ProQR Therapeutics N.V. business relationships
Companies named in ProQR Therapeutics N.V.’s 20-F filed 2026-03-12, and public companies whose annual reports name ProQR Therapeutics N.V.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in ProQR Therapeutics N.V.’s annual report 2
“To date the Lilly collaboration has been the main source of revenue to the Company.” SEC filing
“License Agreement between Ionis Pharmaceuticals, Inc. and the Registrant dated as of October 26, 2018 (incorporated by reference to Exhibit 4.17 to the Registrant's Annual Report on Form 20-F for the fiscal year ended December 31, 2018 (File No. 001-36622) filed on March 28, 2019)” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.